|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
6 months to Dec 31, 2022
|
FY2021
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Product manufacturing and operating costs | |||||
| Administrative and other expenses | |||||
| Depreciation and amortization expenses | |||||
| Loss on equity investment securities at fair value through profit or loss | |||||
| Research and development costs | |||||
| Share based compensation | |||||
| Employee benefits expense | |||||
| Borrowing costs | |||||
| Foreign currency (loss) gain | |||||
| Loss on extinguishment of convertible notes | |||||
| Impairment of property, plant and equipment | |||||
| (Loss)/gain on fair value of derivative financial instruments | |||||
| Other income, net | |||||
| Loss before income tax (expense) benefit | |||||
| Income tax (expense) benefit | |||||
| Net loss | |||||
| Other comprehensive income / (loss), net of tax | |||||
| Foreign currency translation of foreign operations | |||||
| Total comprehensive loss | |||||
| Net loss per share attributable to the ordinary equity holders - basic | |||||
| Net loss per share attributable to the ordinary equity holders - diluted | |||||
| Weighted average shares outstanding - basic | |||||
| Weighted average shares outstanding - diluted | |||||
Loading...